ROVI has commenced the marketing of its enoxaparin biosimilar in Spain

ROVI – Commencement of the marketing of its enoxaparin biosimilar in Spain 1 For more information: Investor Relations (Tel: +34 91 244 44 22) Marta Campos Martínez [email protected] ROVI has commenced the marketing of its enoxaparin biosimilar in Spain Madrid, 19 September 2018 – This month, September 2018, Laboratorios Farmacéuticos ROVI has commenced the marketing of i ts enoxaparin biosimilar (low-molecular-weight heparin) in Spain under the b rand name “Enoxaparina Rovi®”. Spain is one of the main enoxaparin markets in Euro pe. According to QuntilesMS (2015), the enoxaparin market totals more than 1,000 million euros in Europe, with a market share of 75% concentrated in Germany, France, Spain, the United Kingdom, Portugal and Poland, countries in which ROVI hopes to market its product directly through its subsidiaries. With the launch of the enoxaparin biosimilar in Spa in, ROVI expands the product’s presence in Europe, which began in Septem ber 2017, when it was first marketed in Germany, and was then extended to the United Kingdom and Italy in the first half of 2018. ROVI’s enoxaparin sodium is an anticoagulant medicine belonging to the low- molecular-weight heparin group. It is used to treat and prevent deep vein thrombosis and pulmonary embolism. As of 30 June 20 18, ROVI had obtained authorization for the marketing of its enoxaparin b iosimilar from the competent national authorities in 21 European countries. ROVI – Commencement of the marketing of its enoxaparin biosimilar in Spain 2 About ROVI ROVI is a pan-European pharmaceutical company speci alizing and engaging in the research, development, contract manufacturing a nd marketing of small molecules and biological specialties. The company, in a continuous international expansion process, has subsidiaries in Portugal, Ge rmany, the United Kingdom, Italy and France and a diversified marketing portfolio of more than 40 products, among which its flagship product, Bemiparin, alread y marketed in 56 countries all over the world, should be highlighted. Likewise , in 2017, ROVI commenced the marketing of its enoxaparin biosimilar, developed in-house, in Europe. ROVI continues to develop the ISM® Platform technology, a leading-edge line of research in the field of prolonged drug release wit h proven advantages. For more information, please visit www.rovi.es

The release as fetched from its publisher. rovi.es ↗